Sanara MedTech Q4 revenue $17.7M, up 15.5% YoY; FY23 revenue $65.0M, up 41.8% YoY

Sanara MedTech Inc.

2023-FY EPS reported -$0.52 revenue$64,989,842

Q4 net revenue $17.7M, +15.5% YoY; ninth consecutive record quarter.
FY23 net revenue $65.0M, +41.8% YoY vs $45.8M in FY22.
CellerateRX Surgical sales +31% YoY; growth driven by soft tissue repair and bone fusion products.
Cash balance $5.1M as of Dec 31, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sanara MedTech Inc. reported preliminary financial results for fourth quarter and full year 2023.

Period: fourth quarter and full year 2023
Result: preliminary results

Exact text from the filing

On February 22, 2024, Sanara MedTech Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the fourth quarter and full year 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Sanara MedTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-007546

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.